Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
BioVie Announces Closing of Acquisition of BioPharma Assets from Privately Held NeurMedix
Details : The acquired assets include NE3107, a selective inhibitor of inflammatory ERK signaling that reduces neuroinflammation. It is an orally administered novel small molecule that inhibits inflammation-driven insulin resistance and major pathological inflamma...
Brand Name : NE3107
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 11, 2021
BioVie Acquires Biopharma Assets from Privately Held NeurMedix
Details : NeurMedix’s lead clinical drug candidate, NE3107, 17α-ethynyl-androst-5-ene-3,7,17-triol, is a first-in-class small molecule, orally administered, highly effective inhibitor of insulin resistance and the pathological inflammatory cascade and with a no...
Brand Name : NE3107
Molecule Type : Undisclosed
Upfront Cash : Undisclosed
April 27, 2021
NeurMedix Obtains FDA Authorization for Pivotal Phase 3 Alzheimer’s Trial
Details : The trial will evaluate twice daily 20 mg oral NE3107 versus placebo for 30 weeks beginning with dose titration of 5 mg BID in weeks 1 and 2 and 10 mg BID in weeks 3-4, with 20 mg BID for weeks 5-30.
Brand Name : NE3107
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 02, 2021
LOOKING FOR A SUPPLIER?
Reset All
